about
Herpes simplex encephalitis : from virus to therapy.Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals.The CXCL12/CXCR4 Signaling Pathway: A New Susceptibility Factor in Human Papillomavirus Pathogenesis[Herpes simplex virus meningitis in 11 patients].Epidemiological and clinical characteristics of patients infected with enterovirus D68, France, July to December 2014.Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions.Complementary assays for monitoring susceptibility of varicella-zoster virus resistance to antivirals.Molecular characterization of herpes simplex virus 2 strains by analysis of microsatellite polymorphism.Adapted treatment of Epstein-Barr virus infection to prevent posttransplant lymphoproliferative disorder after heart transplantation.Detection of pandemic (H1N1) 2009 virus in patients treated with oseltamivir.Utilization of microsatellite polymorphism for differentiating herpes simplex virus type 1 strainsSuccessful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.Epstein-Barr virus load in whole blood correlates with HIV surrogate markers and lymphoma: a French national cross-sectional study.Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation.Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR.Length variability of telomeric repeat sequences of human herpesvirus 6 DNA.Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.Phenotypic and genotypic characterization of acyclovir-resistant corneal HSV-1 isolates from immunocompetent patients with recurrent herpetic keratitis.Detection of human herpesviruses HHV-6, HHV-7 and HHV-8 in whole blood by real-time PCR using the new CMV, HHV-6, 7, 8 R-gene kit.Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection.[The CXCL12/CXCR4 signaling pathway in the control of human papillomavirus infection: new susceptibility factors in viral pathogenesis].Mutation in the L3 Ribosomal Protein Could Be Associated with Risk of Selection of High-Level Linezolid-Resistant Staphylococcus epidermidis Strains.[Evaluation of the LightCycler 480 real-time PCR system for the measurement of CMV, EBV, HHV-6 and BKV viral loads in whole blood].Use of the Roche LightCycler 480 system in a routine laboratory setting for molecular diagnosis of opportunistic viral infections: Evaluation on whole blood specimens and proficiency panels.Antiviral effects of Cacicol, a heparan sulfate biomimetic for corneal regeneration therapy, for herpes simplex virus type-1 and varicella zoster virus infectionConservation of HHV-6 DNA polymerase processivity factor sequence and predicted structure suggests it as a target for antiviral developmentMicrosatellite analysis of HSV-1 isolates: From oropharynx reactivation toward lung infection in patients undergoing mechanical ventilationGenetic analysis and putative role in resistance to antivirals of the human cytomegalovirus DNA polymerase UL44 processivity factorMonitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole bloodMulticentric evaluation of a new commercial cytomegalovirus real-time PCR quantitation assayHerpes Simplex Virus 1 Replication, Ocular Disease, and Reactivations from Latency Are Restricted Unilaterally after Inoculation of Virus into the LipIdentification by high-throughput sequencing of HPV variants and quasispecies that are untypeable by linear reverse blotting assay in cervical specimens
P50
Q34177932-E24E1B02-E9D3-434E-924D-C2B168B7BDA1Q34290117-B55C628F-B3AC-47A2-939C-CDAD759EA0F1Q36213484-84B34E12-9949-4374-A038-8400D307C031Q40429663-3F26CB46-FC36-4500-B745-D4122C0CA82EQ40668086-B7FD56EB-72A0-455B-A2A6-895FE25ADA78Q40675626-323D081C-D537-4D83-B382-509FF661FC8DQ40748817-DBDB82ED-D47D-41B9-AD17-C4850CC93B80Q41868018-A3D9AECA-3768-451E-9893-B149F5B3486AQ42229199-6CDD6777-7B49-4BD2-9F74-96F2E2617F79Q42407739-1A0E61FE-7F9B-48E8-B57F-53BF62D3E004Q42607544-826307A9-57F9-4218-84BD-806C7C65FABCQ45361068-775802F5-E687-4E1A-884C-883C006F154BQ45385711-DF7FED49-26BC-4502-B62F-231DE3B2E8C8Q45408186-3A9C43ED-7939-4376-BDEA-A233E9A30B04Q45421107-3B3476BC-13AC-405C-A51C-70BD66FD2BCCQ46011811-1EBE5DA1-A2F1-4F52-8338-32F084AF1793Q46209853-487ABC1C-A740-4BD4-9BFE-5F1C0AD7BBC4Q46380505-F1EBFBB8-08E7-4E51-9FA0-36E809CA189EQ46711190-C4B57F95-335A-4445-A959-395AC24B6997Q46777733-A11DCB53-0EFD-4404-908E-31C2DCFA8E07Q49846091-8A1C7F08-BEB2-444D-ADED-FCB91739EA56Q51380424-FC1F9552-6ED5-46AD-A553-7A65F3F250C9Q54455882-61C667E7-475B-4AD6-B16C-5876DAFF9495Q54479660-4483A5FE-CFED-44F2-A9EE-A2856D5B7E48Q59356386-C166AE2B-ABE8-4800-8BE0-A310ACFC4149Q62066476-EE52E4F7-F8C2-4572-83B1-5714475DEFA8Q62066483-C64A528E-DCA1-4A1E-A5AE-257B70676035Q62066488-5217FB52-97AE-46D3-BB8E-386178283CF0Q62066496-44FB61D1-4523-49F8-B83C-C0F3B1359A73Q62066497-D55C5B3F-886F-4AD6-8AAC-1F157061C333Q90286933-294B9C31-5CE0-497E-A5EB-3AA4876ED9D8Q91711292-B2F1AD1F-4BA1-43D0-A9C8-AEFC22E5B694
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claire Deback
@ast
Claire Deback
@en
Claire Deback
@es
Claire Deback
@nl
Claire Deback
@sl
type
label
Claire Deback
@ast
Claire Deback
@en
Claire Deback
@es
Claire Deback
@nl
Claire Deback
@sl
prefLabel
Claire Deback
@ast
Claire Deback
@en
Claire Deback
@es
Claire Deback
@nl
Claire Deback
@sl
P1053
B-2787-2014
P106
P1153
22633444800
P21
P31
P3829
P496
0000-0001-9465-2381